Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
08037 China Biotech Services
1.080
-0.020-1.82%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Turnover
152.42% 1.28B 83.59% 686.91M 149.13% 384.09M -4.88% 623.76M
Operating income
152.42% 1.28B 83.59% 686.91M 149.13% 384.09M -4.88% 623.76M
Cost of sales
-154.70% -539.44M -110.66% -332.01M -146.18% -194.36M 16.09% -265.74M
Operating expenses
-154.70% -539.44M -110.66% -332.01M -146.18% -194.36M 16.09% -265.74M
Gross profit
150.78% 736.31M 63.88% 354.9M 152.24% 189.73M 5.59% 358.02M
Selling expenses
-11.87% -10.19M -74.63% -10.71M -24.44% -3.91M 1.05% -11.72M
Administrative expenses
-49.38% -157.56M -47.69% -93.83M -62.60% -54.34M -18.56% -157.08M
Revaluation surplus
-- -- -- 2.71M -- 1.97M -- --
-Changes in the fair value of financial assets
-- -- -- 2.71M -- 1.97M -- --
Impairment and provision
-- 859K -- -- -- -- 78.08% -251K
-Other impairment is provision
-- 859K -- -- -- -- 78.08% -251K
Special items of operating profit
308.01% 1.78M 897.94% 3.87M -199.01% -200K -87.63% 714K
Operating profit
218.29% 571.21M 74.46% 256.95M 242.88% 133.26M -4.86% 189.68M
Financing cost
38.35% -3.26M 43.33% -2.31M 46.62% -1.22M -0.69% -6.54M
Share of profit from joint venture company
-- -2.46M -- -1.03M -- -- -- --
Special items of earning before tax
207.06% 4.82M 103.37% 152K -- -- -124.84% -2.47M
Earning before tax
236.12% 570.31M 82.95% 253.76M 260.92% 132.04M -10.91% 180.67M
Tax
-182.43% -106.7M -59.51% -47.4M -172.41% -25.46M -36.72% -48.1M
After-tax profit from continuing operations
251.51% 463.61M 89.34% 206.36M 291.30% 106.59M -20.91% 132.57M
Earning after tax
251.51% 463.61M 89.34% 206.36M 291.30% 106.59M -20.91% 132.57M
Minority profit
190.61% 304.09M 63.00% 138.14M 181.85% 71.65M -17.65% 113.19M
Profit attributable to shareholders
485.29% 159.52M 181.45% 68.22M 1,820.73% 34.94M -35.75% 19.39M
Basic earnings per share
492.86% 0.166 184.00% 0.071 1,700.00% 0.036 -35.48% 0.02
Diluted earnings per share
492.86% 0.166 184.00% 0.071 1,700.00% 0.036 -35.48% 0.02
Currency Unit
HKDHKDHKDHKD
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
------Unqualified Opinion
Auditor
------Luo Shenmei accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
China Biotechnology Services Holdings Limited was established as a Sino-foreign joint venture in China in 1996 and was listed on the gem of the Hong Kong Stock Exchange in June 2004 under the stock code 8037.HK, referred to as "China Biotechnology Services". The company was included in the Hong Kong MSCI Micro-share Index in May 2018. Our vision: Future biotechnology platform The layout of "accurate diagnosis: accurate Great Health Inspection system" and "accurate treatment: Car-T Integrated Industry chain" ▎ based on Guangdong-Hong Kong-Macau Greater Bay Area facing China and Europe and the United States Seize the historical opportunity of global precision medical development and strive to become a future biotechnology platform Company philosophy: Cover various human states of health, sub-health and disease, through the combination of individual life numbers and big data's life cycle table, recognize and control customer health throughout the life cycle, and formulate targeted intervention measures. make the disease knowable, controllable and treatable.
CEO: Xiaolin Liu
Market: GEM
Listing Date: 06/17/2004
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist